Human life expectancy has doubled since the 1900s, mostly attributed to advancements in lifestyle, living standards and medicine. Thanks to biotech companies that produce transformative drugs and treatments, we now have the collective ability to combat diseases that used to bring entire nations down.
Small- and mid-cap stocks are known to be highly sensitive to interest rates. With the Federal Reserve expected to start cutting rates no later than 2025, these equities may be on the verge of a turnaround.